HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dietary Supplement Ads Most Common Among Cases NAD Picks To Review

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement advertising accounted for "the largest share" of the cases the National Advertising Division of the Council of Better Business Bureaus identified through active monitoring in the past five years, says NAD Associate Director David Mallen

You may also be interested in...



Gabatrol Ingredient-Specific Claims Do Not Apply To Overall Product – NAD

Dietary supplement manufacturer Pure Life should not imply in ads that ingredient-specific claims apply to an overall product "in the absence of testing on the product itself," according to an April 2 National Advertising Division decision

Do Not Disrespect NAD: FTC Stresses Compliance With Self-Regulatory Groups

The decision by the maker of Sunpill sunscreen tablets not to comply with the National Advertising Division's recommendations to change its advertising claims is an uncommon response that will get the Federal Trade Commission's attention, Lesley Fair, senior attorney in FTC's Division of Consumer Education, says

CRN Grants $500K To NAD For Increased Dietary Supplement Monitoring

CRN is committing nearly half a million dollars over a three year period to triple the annual number of dietary supplement cases reviewed by the Council of Better Business Bureaus' National Advertising Division (NAD)

Related Content

Topics

UsernamePublicRestriction

Register

RS137389

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel